An all-in-one strategy for the simultaneous production of bioplastics and degrading enzymes in engineered Escherichia coli
Enzyme and Microbial Technology · 2025
DOI: 10.1016/j.enzmictec.2025.110593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enzyme and Microbial Technology, 2025. Verfasst von Suwon Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Engineering, Advanced Materials Program, College of Engineering, Konkuk University, 120, Neungdong-ro, Gwangjin-gu, Seoul, R…. Hauptthemen laut MEDLINE: Escherichia coli, Metabolic Engineering, Hydroxybutyrates, Lipase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Korea Evaluation Institute of Industrial Technology, Korea Forest Service, Korea Forestry Promotion Institute.
Abstract (Originalsprache)
Bioplastics are promising alternatives for traditional plastics, which contribute significantly to environmental pollution and have a detrimental impact on ecosystems. To advance their use, further research into bioplastic biodegradation is essential. In this study, we propose a novel approach for simultaneous polyhydroxybutyrate (PHB) and degrading enzyme production in a single-cell system using engineered Escherichia coli. Typically, PHB depolymerases, such as PhaZ, disrupt bioplastic synthesis in cells, leading to a self-defeating cycle of production and degradation. To counter this, we introduced synthetic PHB production genes and triacylglycerol lipase (TGL) from Bacillus sp. JY35, along with a native signal peptide for secretion. This enabled PHB accumulation inside the cells while TGL was secreted into the supernatant. The concentrations of PHB produced with and without TGL were similar (31.44 % PHB with TGL and 32.12 % PHB without TGL). TGL was efficiently secreted in E. coli, achieving specific esterase activities of 7.1 U/mg and 15.7 U/mg for p-Nitrophenyl butyrate and p-nitrophenyl octanoate, respectively, and degraded PHB film by 30.1 % over 14 d. Moreover, TGL retained 86 % and 91 % of its activities for the C4 and C8 substrates, respectively, after 30 d of storage at room temperature, suggesting potential use PHB degradation after use. Our study demonstrates a straightforward one-month circular cycle for bioplastic production and degradation by a single producer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Engineering, Advanced Materials Program, College of Engineering, Konkuk University, 120, Neungdong-ro, Gwangjin-gu, Seoul, Republic of Korea.
- Department of Biological and Chemical Engineering, Hongik University, Sejong, Republic of Korea.
- Department of Biological Engineering, Advanced Materials Program, College of Engineering, Konkuk University, 120, Neungdong-ro, Gwangjin-gu, Seoul, Republic of Korea. Electronic address: seokor@konkuk.ac.kr.
Förderung
- Korea Evaluation Institute of Industrial Technology
- Korea Forest Service
- Korea Forestry Promotion Institute
- National Research Foundation of Korea
- Ministry of Trade, Industry and Energy
Zitieren
APA
Kim, S., Han, Y., Lim, G., Park, S. H., Park, K., Bhatia, S. K., & Yang, Y. H. (2025). An all-in-one strategy for the simultaneous production of bioplastics and degrading enzymes in engineered Escherichia coli. Enzyme and Microbial Technology. https://doi.org/10.1016/j.enzmictec.2025.110593
Vancouver
Kim S, Han Y, Lim G, Park SH, Park K, Bhatia SK, et al. An all-in-one strategy for the simultaneous production of bioplastics and degrading enzymes in engineered Escherichia coli. Enzyme and Microbial Technology. 2025. doi:10.1016/j.enzmictec.2025.110593
BibTeX
@article{Kim2025,
author = {Kim, Suwon and Han, Yebin and Lim, Gaeun and Park, See-Hyoung and Park, Kyungmoon and Bhatia, Shashi Kant and Yang, Yung-Hun},
title = {An all-in-one strategy for the simultaneous production of bioplastics and degrading enzymes in engineered Escherichia coli},
journal = {Enzyme and Microbial Technology},
year = {2025},
doi = {10.1016/j.enzmictec.2025.110593}
}
EUVIMED